(S) -JQ-35

(S) -JQ-35 (TEN-010) is a selective bromodomain and extra-terminal domain (BET) protein family inhibitor targeting BRD4, BRD3, BRD2 and BRDT. (S) -JQ-35 is orally active and can penetrate the blood-brain barrier. (S) -JQ-35 competitively binds to the bromodomain of BRD4, preventing it from binding to the Myc gene promoter, thereby inhibiting cancer cell proliferation and inducing cell apoptosis. (S) -JQ-35 can be used for targeted therapy research of malignant tumors such as NUT midline carcinoma and refractory solid tumors[1][2].

Product Specifications

CAS Number

[1349719-98-7]

Product Name Alternative

TEN-010

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/JQ-35,__S_-.html

Purity

99.46

Solubility

DMSO : ≥ 85 mg/mL

Smiles

O=C(NCCCN1CCN(C)CC1)C[C@H]2C3=NN=C(C)N3C4=C(C(C)=C(C)S4)C(C5=CC=C(Cl)C=C5)=N2

Molecular Formula

C27H34ClN7OS

Molecular Weight

540.12

Precautions

H302, H315, H319

References & Citations

[1]Samples S, et al. Intrapericardial NUT Midline Carcinoma: Unusual Presentation of a Rare Tumor and Literature Review with Management Considerations. Pediatr Cardiol. 2016 Jan;37 (1) :208-11.|[2]Sharifi Z, et al. Pharmacokinetics of ZR2002, a combi-molecule with EGFR and DNA-damaging properties and its efficacy in an orthotopic glioblastoma mouse model[J]. Annals of Oncology, 2018, 29: iii12.